Pharmaceutical and Life Sciences Real World Evidence (2nd Edition), 2021-2030: Distribution by Applications, Real World Data Sources, Key Therapeutic Areas and Geography

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Need for Real World Evidence
3.2.1. Growing Concerns Related to Chronic Disorders
3.2.2. High Investments in Drug Development
3.2.3. Role of Randomized Clinical Trials
3.2.4. Shift from Volume- to Value-based Care

3.3. Overview of Real World Evidence
3.3.1. Sources of Real World Data
3.3.1.1. Medical Claims Data
3.3.1.2. Clinical Trial Data
3.3.1.3. Patient-powered Data
3.3.1.4. Pharmacy Data
3.3.1.5. Other Real World Data Sources

3.3.2. Comparison of Randomized Clinical Trials and Real World Evidence
3.3.3. Advantages and Limitations of Real World Evidence
3.3.4. Potential Applications of Real World Evidence
3.3.5. Growth Drivers and Challenges

3.4. Role of Advanced Techniques in Real World Data Management
3.5. Future Perspectives

4. DATA GOVERNANCE AND REGULATORY FRAMEWORK FOR REAL WORLD EVIDENCE
4.1. Chapter Overview
4.2. Primary Elements of Data Governance for Real World Evidence
4.3. Importance of Regulatory Framework for Real World Evidence

4.4. Data Governance and Regulatory Framework in North America
4.4.1. The US Scenario
4.4.1.1. Data Governance
4.4.1.2. Regulatory Framework

4.4.2. The Canadian Scenario
4.4.2.1. Data Governance
4.4.2.2. Regulatory Framework

4.5. Data Governance and Regulatory Framework in Europe
4.5.1. The UK Scenario
4.5.1.1. Data Governance
4.5.1.2. Regulatory Framework

4.5.2. The German Scenario
4.5.2.1. Data Governance
4.5.2.2. Regulatory Framework

4.5.3. The French Scenario
4.5.3.1. Data Governance
4.5.3.2. Regulatory Framework

4.5.4. The Spanish Scenario
4.5.5. The Italian Scenario

4.6. Data Governance and Regulatory Framework in Asia-Pacific and Rest of the World
4.6.1. The Australian Scenario
4.6.2. The Chinese Scenario
4.6.3. The Japanese Scenario

5. CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Real World Evidence Solution Providers: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Type of Business Model
5.2.5. Analysis by Type of Services Offered
5.2.6. Analysis by Real World Data Source
5.2.7. Analysis by Key Applications of Real World Evidence
5.2.8. Analysis by Key Therapeutic Areas

6. COMPANY PROFILES 
6.1. Chapter Overview
6.2. Clinerion
6.2.1. Company Overview
6.2.2. Technology Overview
6.2.3. Recent Developments and Future Outlook

6.3. Clinigen Group
6.3.1. Company Overview
6.3.2. Recent Developments and Future Outlook

6.4. Cognizant Analytics
6.4.1. Company Overview
6.4.2. Recent Developments and Future Outlook

6.5. Evidera
6.5.1. Company Overview
6.5.2. Technology Portfolio
6.5.3. Recent Developments and Future Outlook

6.6. HealthCore
6.6.1. Company Overview
6.6.2. Recent Developments and Future Outlook

6.7. IBM
6.7.1. Company Overview
6.7.2. Technology Portfolio
6.7.3. Recent Developments and Future Outlook

6.8. ICON
6.8.1. Company Overview
6.8.2. Technology Portfolio
6.8.3. Recent Developments and Future Outlook

6.9. IQVIA
6.9.1. Company Overview
6.9.2. Technology Portfolio
6.9.3. Recent Developments and Future Outlook

6.10. Medpace
6.10.1. Company Overview
6.10.2. Technology Overview
6.10.3. Recent Developments and Future Outlook

6.11. NorthWest EHealth
6.11.1. Company Overview
6.11.2. Technology Overview
6.11.3. Recent Developments and Future Outlook

6.12. Optum Insight
6.12.1. Company Overview
6.12.2. Recent Developments and Future Outlook

6.13. Oracle
6.13.1. Company Overview
6.13.2. Technology Portfolio
6.13.3. Recent Developments and Future Outlook
6.14. PAREXEL
6.14.1. Company Overview
6.14.2. Technology Overview
6.14.3. Recent Developments and Future Outlook

6.15. Perkin Elmer
6.15.1. Company Overview
6.15.2. Recent Developments and Future Outlook

6.16. SAS
6.16.1. Company Overview
6.16.2. Technology Portfolio
6.16.3. Recent Developments and Future Outlook

6.17. Syneos Health
6.17.1. Company Overview
6.17.2. Recent Developments and Future Outlook

6.18. TriNetX
6.18.1. Company Overview
6.18.2. Technology Overview
6.18.3. Recent Developments and Future Outlook

7. CLINICAL TRIAL ANALYSIS 
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Real World Evidence: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Recruitment Status
7.3.3. Analysis by Type of Study
7.3.4. Analysis by Type of Sponsor / Collaborator
7.3.5. Most Active Players: Analysis by Number of Trials
7.3.6. Geographical Analysis by Number of Clinical Trials
7.3.7. Geographical Analysis by Enrolled Patient Population
7.3.8. Emerging Focus Areas
7.3.9. Analysis by Key Therapeutic Areas
7.3.10. Grid Representation: Analysis by Key Therapeutic Areas, Number of Trials and Leading Players
7.3.11. Benchmark Analysis of Key Industry Players

8. PUBLICATION ANALYSIS 
8.1. Chapter Overview
8.2. Scope and Methodology

8.3. Real World Evidence: Recent Publications
8.3.1. Analysis by Year of Publication
8.3.2. Analysis by Emerging Focus Areas
8.3.3. Analysis by Real World Data Sources
8.3.4. Analysis by Key Indications Examined
8.3.5. Leading Players: Analysis by Number of Publications
8.3.6. Geographical Analysis by Number of Publications

8.3.7. Analysis by Key Research Journals
8.3.7.1. Key Journals: Analysis by Number of Publications
8.3.7.2. Key Journals: Analysis by Journal Impact Factor

8.3.8. Most Popular Authors: Analysis by Number of Publications

9. EMERGING TRENDS ON SOCIAL MEDIA
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Real World Evidence: Trends on Twitter
9.3.1. Historical Trends in Volume of Tweets
9.3.2. Popular Keywords
9.3.3. Popular Real World Data Sources
9.3.4. Popular Applications of Real World Evidence
9.3.5. Popular Therapeutic Areas
9.3.6. Popular Stakeholders
9.3.7. Most Prolific Contributors
9.3.8. Most Influential Contributors

10. GLOBAL EVENTS ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Real World Evidence: Global Events Analysis
10.3.1. Analysis by Year of Occurrence
10.3.2. Analysis by Event Platform
10.3.3. Analysis by Type of Event 
10.3.4. Analysis by Geography 
10.3.5. Evolutionary Trends in Key Focus Area / Event Agenda
10.3.6. Most Active Event Organizers
10.3.7. Most Active Participants: Analysis by Number of Events
10.3.8. Analysis by Seniority Level of Participants
10.3.9. Geographical Mapping of Upcoming Events

11. STAKEHOLDER NEEDS ANALYSIS
11.1. Chapter Overview
11.2. Real World Evidence: Approaches for Data Generation
11.3. Real World Evidence: Needs of Different Stakeholders
11.4. Real World Evidence: Comparison of Needs of Various Stakeholders
11.4.1. Needs of Healthcare Providers
11.4.2. Needs of Manufacturers
11.4.3. Needs of Payers
11.4.4. Needs of Patients
11.4.5. Needs of Regulators

12. KEY ACQUISITION TARGETS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Scoring Criteria and Key Assumptions
12.4. Potential Strategic Acquisition Targets in North America
12.5. Potential Strategic Acquisition Targets in Europe
12.6. Potential Strategic Acquisition Targets in Asia-Pacific and Rest of the World
12.7. Concluding Remark

13. SWOT ANALYSIS
13.1. Chapter Overview
13.2. Real World Evidence: SWOT Analysis
13.2.1. Comparison of SWOT Factors

14. COST SAVING AND MARKET OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Real World Evidence Use Cases
14.3. Real World Evidence Market Opportunity Assessment
14.3.1 Methodology and Key Assumptions

14.4. Overall Real World Evidence Market Opportunity in Drug Development, 2021-2030
14.4.1. Real World Evidence Market Opportunity across Different Type of Sources
14.4.1.1. Real World Evidence Market Opportunity from Medical Claims Data, 2021-2030
14.4.1.2. Real World Evidence Market Opportunity from Clinical Trials Data, 2021-2030
14.4.1.3. Real World Evidence Market Opportunity from Clinical Settings Data, 2021-2030
14.4.1.4. Real World Evidence Market Opportunity from Patient-Powered Data, 2021-2030
14.4.1.5. Real World Evidence Market Opportunity from Other Types of Data, 2021-2030

14.4.2. Overall Real World Evidence Market Opportunity across Different Therapeutic
14.4.2.1. Real World Evidence Market Opportunity for Autoimmune Disorders, 2021-2030
14.4.2.2. Real World Evidence Market Opportunity for Cardiovascular Disorders, 2021-2030
14.4.2.3. Real World Evidence Market Opportunity for Infectious Diseases, 2021-2030
14.4.2.4. Real World Evidence Market Opportunity for Metabolic Disorders, 2021-2030
14.4.2.5. Real World Evidence Market Opportunity for Neurological / Psychiatric Disorders, 2021-2030
14.4.2.6. Real World Evidence Market Opportunity for Oncological Disorders, 2021-2030
14.4.2.7. Real World Evidence Market Opportunity for Respiratory Disorders, 2021-2030
14.4.2.8. Real World Evidence Market Opportunity for Other Disorders, 2021-2030

14.4.3. Overall Real World Evidence Market Opportunity across Different Areas of
14.4.3.1. Real World Evidence Market Opportunity in Early Stage Research, 2021-2030
14.4.3.2. Real World Evidence Market Opportunity in Clinical Development, 2021-2030
14.4.3.3. Real World Evidence Market Opportunity in Regulatory Approval, 2021-2030
14.4.3.4. Real World Evidence Market Opportunity in Pricing / Reimbursement, 2021-2030
14.4.3.5. Real World Evidence Market Opportunity in Post-Approval Studies, 2021-2030

14.4.4. Overall Real World Evidence Market Opportunity across Different Geographies
14.4.4.1. Real World Evidence Market Opportunity in North America, 2021-2030
14.4.4.2. Real World Evidence Market Opportunity in Europe, 2021-2030
14.4.4.3. Real World Evidence Market Opportunity in Asia-Pacific, 2021-2030
14.4.4.4. Real World Evidence Market Opportunity in Latin America, 2021-2030
14.4.4.5. Real World Evidence Market Opportunity in Middle East and North Africa (MENA), 2021-2030
14.4.4.6. Real World Evidence Market Opportunity in Rest of the World (RoW), 2021-2030

14.5. Concluding Remarks

15. SURVEY INSIGHTS
15.1. Chapter Overview
15.2. Analysis by Designation of Respondents
15.3. Analysis by Type of Services Offered
15.4. Analysis by Real World Data Sources
15.5. Analysis by Applications of Real World Evidence
15.6. Analysis by Key Challenges in Generating Real World Evidence
15.7. Analysis by Extent of Outsourcing
15.8. Current Annual Budget for Real World Evidence

16. IMPACT OF COVID-19 ON REAL WORLD EVIDENCE MARKET
16.1. Chapter Overview
16.2. Current Options and Recuperative Initiatives of Key Players
16.3. Impact on Real World Evidence Market Opportunity

17. CONCLUSION

18. INTERVIEW TRANSCRIPTS
18.1. Chapter Overview
18.2. Limor BH Epstein, Founder, Data2Life
18.3. Anonymous, Vice President, Big Pharmaceutical Company 
18.4. Wirth Peter, Vice President, RTI Health Solutions
18.5. Douglas Drake (Senior Director, Clinerion)
18.6. Fernando Santa (Chief Operating Officer, Adarna Health Data)
18.7. Jonathan Moshinsky, Head of Market Strategy, uMotif
18.8. Anonymous, Savana

19. APPENDIX 1: TABULATED DATA

20. APPENDIX II: LIST OF COMPANIES AND ORGANIZATION

List of Figures

Figure 3.1 Role of Real World Data in Shaping Healthcare Decision-making
Figure 3.2 Common Types of Chronic Disorders and their Rapidly Increasing Prevalence
Figure 3.3 Drug Development Costs: Historical Trend (USD Million)
Figure 3.4 Limitations of Randomized Clinical Trials
Figure 3.5 Traditional versus Outcome-based Development Model
Figure 3.6 Process of Generating Evidence from Real World Data
Figure 3.7 Type of Real World Data Sources
Figure 3.8 Different Constituents of Real World Data Sources
Figure 3.9 Randomized Clinical Trials versus Real World Evidence
Figure 3.10 Potential Applications of Real World Evidence
Figure 3.11 Potential Applications of Real World Evidence across Different Stages of Drug Development and Commercialization: A Summary
Figure 3.12 Growth Drivers and Potential Roadblocks of Real World Evidence
Figure 4.1 Real World Evidence: Primary Elements of Data Governance
Figure 4.2 Real World Evidence: Ideal Regulatory Framework
Figure 4.3 Emergence of Real World Evidence in China
Figure 5.1 Real World Evidence Solution Providers: Distribution by Year of Establishment
Figure 5.2 Real World Evidence Solution Providers: Distribution by Company Size
Figure 5.3 Real World Evidence Solution Providers: Distribution by Location of Headquarters
Figure 5.4 Real World Evidence Solution Providers: Distribution by Type of Business Model
Figure 5.5 Real World Evidence Solution Providers: Distribution by Type of Services Offered
Figure 5.6 Real World Evidence Solution Providers: Distribution by Real World Data Source
Figure 5.7 Real World Evidence Solution Providers: Distribution by Key Applications of Real World Evidence
Figure 5.8 Real World Evidence Solution Providers, Grid Analysis: Distribution by Company Size, Type of Offering and Applications of Real World Evidence
Figure 5.9 Real World Evidence Solution Providers: Distribution by Key Therapeutic Areas
Figure 7.1 Clinical Trial Analysis: Distribution by Trial Status
Figure 7.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year
Figure 7.3 Clinical Trial Analysis: Geographical Distribution by Number of Trials
Figure 7.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Figure 7.5 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 7.6 Clinical Trial Analysis: Dot Plot of Number of Trials and Enrolled Patient Population
Figure 7.7 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 7.8 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Trial Recruitment Status
Figure 7.9 Clinical Trial Analysis: Distribution by Type of Study
Figure 7.10 Clinical Trial Analysis: Distribution by Trial Registration Year and Type of Study
Figure 7.11 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 7.12 Clinical Trial Analysis: Most Active Industry Players
Figure 7.13 Clinical Trial Analysis: Most Active Non-Industry Players
Figure 7.14 Clinical Trial Analysis: Evolutionary Trends in Key Focus Areas
Figure 7.15 Clinical Trial Analysis: Distribution by Key Therapeutic Areas
Figure 7.16 Clinical Trial Analysis: Distribution by Trial Registration Year and Key Therapeutic Areas
Figure 7.17 Clinical Trial Analysis: Leading Indications
Figure 7.18 Grid Representation: Distribution by Key Therapeutic Areas, Number of Trials and Leading Players
Figure 7.19 Clinical Trial Analysis: Year Wise Trend of Trials Conducted by Leading Industry Players, 2013-2020
Figure 7.20 Clinical Trial Analysis: Benchmarking of Leading Industry Players by Number of Trials across Key Therapeutic Areas
Figure 8.1 Publication Analysis: Distribution by Type of Publication
Figure 8.2 Publication Analysis: Cumulative Year-wise Trend, 2016-Q3 2020
Figure 8.3 Publication Analysis: Distribution by Key Focus Areas
Figure 8.4 Publication Analysis: Word Cloud of Study Titles
Figure 8.5 Publication Analysis: Distribution by Real World Data Sources
Figure 8.6 Publication Analysis: Key Indications (in Terms of Number of Published Studies)
Figure 8.7 Publication Analysis: Distribution by Type of Sponsor
Figure 8.8 Publication Analysis: Most Active Industry Players (in Terms of Number of Published Studies)
Figure 8.9 Publication Analysis: Geographical Distribution of Authors
Figure 8.10 Publication Analysis: Key Journals (in Terms of Number of Published Studies)
Figure 8.11 Publication Analysis: Key Journals (in Terms of Impact Factor)
Figure 8.12 Publication Analysis: Most Popular Authors
Figure 9.1 Trends on Social Media: Historical Activities on Twitter
Figure 9.2 Trends on Social Media: Cumulative Year-wise Distribution (in terms of Volume of Tweets)
Figure 9.3 Trends on Social Media: Most Popular Keywords
Figure 9.4 Trends on Social Media: Most Popular Real World Data Sources
Figure 9.5 Trends on Social Media: Most Popular Applications of Real World Evidence
Figure 9.6 Trends on Social Media: Most Popular Therapeutic Areas
Figure 9.7 Trends on Social Media: Most Popular Stakeholders
Figure 9.8 Trends on Social Media: Most Prolific Contributors
Figure 9.9 Trends on Social Media: Most Influential Contributors
Figure 10.1 Global Events Analysis: Cumulative Quarter-wise Trend, H1 2017-2020
Figure 10.2 Global Events Analysis: Distribution by Event Platform
Figure 10.3 Global Events Analysis: Distribution by Event Location
Figure 10.4 Global Events Analysis: Distribution by Type of Event
Figure 10.5 Global Events Analysis: Evolutionary Trend in Key Focus Areas
Figure 10.6 Global Events Analysis: Historical Trend of Event Agendas, 2017-2020
Figure 10.7 Global Events Analysis: Most Active Event Organizers
Figure 10.8 Global Events Analysis: Most Active Industry Players (in terms of Event Participation)
Figure 10.9 Global Events Analysis: Most Active Non-Industry Players (in terms of Event Participation)
Figure 10.10 Global Events Analysis: Distribution by Designations of Event Participants
Figure 10.11 Global Events Analysis: Distribution by Affiliated Departments of Event Participants
Figure 10.12 Global Events Analysis: Geographical Mapping of Upcoming Events
Figure 11.1 Comparison of Historical and Optimal Approach of Real World Evidence Generation
Figure 11.2 Stakeholder Needs Analysis: Comparison of Stakeholders
Figure 11.3 Stakeholder Needs Analysis: Distribution of Stakeholders based on Real World Data Usability
Figure 11.4 Stakeholder Needs Analysis: Comparison of Needs of Stakeholders
Figure 11.5 Stakeholder Needs Analysis: Distribution of Needs based on Current and Future Relevance
Figure 11.6 Stakeholder Needs Analysis: Needs of Healthcare Providers based on Current and Future Relevance
Figure 11.7 Stakeholder Needs Analysis: Needs of Manufacturers based on Current and Future Relevance
Figure 11.8 Stakeholder Needs Analysis: Needs of Payers based on Current and Future Relevance
Figure 11.9 Stakeholder Needs Analysis: Needs of Patients based on Current and Future Relevance
Figure 11.10 Stakeholder Needs Analysis: Needs of Regulators based on Current and Future Relevance
Figure 12.1 Key Acquisition Targets: Potential Targets in North America
Figure 12.2 Key Acquisition Targets: Potential Targets in Europe
Figure 12.3 Key Acquisition Targets: Potential Targets in Asia-Pacific and Rest of the World
Figure 12.4 Likely Acquisition Targets: Geographical Distribution
Figure 13.1 Real World Evidence: SWOT Analysis
Figure 13.2 Comparison of SWOT Factors
Figure 14.1 Global Real World Evidence Market Opportunity, 2021-2030 (USD Million)
Figure 14.2 Real World Evidence Market Opportunity, 2021-2030: Distribution by Type of Real World Data Source
Figure 14.3 Real World Evidence Market Opportunity from Medical Claims Data, 2021-2030 (USD Million)
Figure 14.4 Real World Evidence Market Opportunity from Clinical Trials Data, 2021-2030 (USD Million)
Figure 14.5 Real World Evidence Market Opportunity from Clinical Settings Data, 2021-2030 (USD Million)
Figure 14.6 Real World Evidence Market Opportunity from Patient-Powered Data, 2021-2030 (USD Million)
Figure 14.7 Real World Evidence Market Opportunity from Other Types of Data, 2021-2030 (USD Million)
Figure 14.8 Real World Evidence Market Opportunity, 2021-2030: Distribution by Therapeutic Areas
Figure 14.9 Real World Evidence Market Opportunity for Autoimmune Disorders, 2021-2030
Figure 14.10 Real World Evidence Market Opportunity for Cardiovascular Disorders, 2021-2030 (USD Million)
Figure 14.11 Real World Evidence Market Opportunity for Infectious Diseases, 2021-2030 (USD Million)
Figure 14.12 Real World Evidence Market Opportunity for Metabolic Disorders, 2021-2030 (USD Million)
Figure 14.13 Real World Evidence Market Opportunity for Neurological / Psychiatric Disorders, 2021-2030 (USD Million)
Figure 14.14 Real World Evidence Market Opportunity for Oncological Disorders, 2021-2030 (USD Million)
Figure 14.15 Real World Evidence Market Opportunity for Respiratory Disorders, 2021-2030 (USD Million)
Figure 14.16 Real World Evidence Market Opportunity for Other Types of Disorders, 2021-2030 (USD Million)
Figure 14.17 Real World Evidence Market Opportunity, 2021-2030: Distribution by Key Applications
Figure 14.18 Real World Evidence Market Opportunity in Early Stage Research, 2021-2030 (USD Million)
Figure 14.19 Real World Evidence Market Opportunity in Clinical Development, 2021-2030 (USD Million)
Figure 14.20 Real World Evidence Market Opportunity in Regulatory Approval, 2021-2030 (USD Million)
Figure 14.21 Real World Evidence Market Opportunity in Pricing / Reimbursement, 2021-2030 (USD Million)
Figure 14.22 Real World Evidence Market Opportunity in Post-Approval Studies, 2021-2030 (USD Million)
Figure 14.23 Real World Evidence Market Opportunity, 2021-2030: Distribution by Geography
Figure 14.24 Real World Evidence Market Opportunity in North America, 2021-2030 (USD Million)
Figure 14.25 Real World Evidence Market Opportunity in Europe, 2021-2030 (USD Million)
Figure 14.26 Real World Evidence Market Opportunity in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.27 Real World Evidence Market Opportunity in Latin America, 2021-2030 (USD Million)
Figure 14.28 Real World Evidence Market Opportunity in MENA, 2021-2030 (USD Million)
Figure 14.29 Real World Evidence Market Opportunity in Rest of the World, 2021-2030 (USD Million)
Figure 14.30 Overall Real World Evidence Market Opportunity, Conservative, Base and Optimistic Scenarios, 2021, 2025 and 2030 (USD Million)
Figure 15.1 Survey Analysis: Distribution by Type of Company
Figure 15.2 Survey Analysis: Distribution by Location of Company
Figure 15.3 Survey Analysis: Distribution by Designation and Seniority Level of Respondents
Figure 15.4 Survey Analysis: Distribution by Types of Services Offered
Figure 15.5 Survey Analysis: Distribution by Real World Data Sources
Figure 15.6 Survey Analysis: Distribution by Applications of Real World Evidence Generation
Figure 15.7 Survey Analysis: Distribution by Key Challenges
Figure 15.8 Survey Analysis: Distribution by Extent of Outsourcing
Figure 15.9 Survey Analysis: Distribution by Average Budget Allocated by Big Pharmaceutical Companies
Figure 16.1 Real World Evidence Market, 2021-2030: COVID-19 Impact Scenario
Figure 17.1 Concluding Remarks: Current Market Landscape
Figure 17.2 Concluding Remarks: Clinical Trial Analysis
Figure 17.3 Concluding Remarks: Publication Analysis
Figure 17.4 Concluding Remarks: Global Events Analysis
Figure 17.5 Concluding Remarks: Key Acquisition Targets
Figure 17.6 Concluding Remarks: Market Sizing and Opportunity Analysis

List of Tables

Table 3.1 Primary Elements of Different Sources of Real World Data
Table 3.2 Real World Evidence: Opportunities in Pharmaceutical and Medical Device Industries
Table 3.3 Randomized Clinical Trials versus Real World Evidence
Table 5.1 Real World Evidence Solution Providers: List of Industry Players
Table 5.2 Real World Evidence Solution Providers: Information on Business Model and Service Offerings
Table 5.3 Real World Evidence Solution Providers: Information on Real World Data Sources
Table 5.4 Real World Evidence Solution Providers: Information on Applications
Table 6.1 List of Companies Profiled
Table 6.2 Clinerion: Company Snapshot
Table 6.3 Clinerion: Recent Developments and Future Outlook
Table 6.4 Clinigen Group: Company Snapshot
Table 6.5 Clinigen Group: Recent Developments and Future Outlook
Table 6.6 Cognizant Analytics: Company Snapshot
Table 6.7 Cognizant Analytics: Recent Developments and Future Outlook
Table 6.8 Evidera: Company Snapshot
Table 6.9 Evidera: Recent Developments and Future Outlook
Table 6.10 HealthCore: Company Snapshot
Table 6.11 HealthCore: Recent Developments and Future Outlook
Table 6.12 IBM: Company Snapshot
Table 6.13 IBM: Recent Developments and Future Outlook
Table 6.14 ICON: Company Snapshot
Table 6.15 ICON: Recent Developments and Future Outlook
Table 6.16 IQVIA: Company Snapshot
Table 6.17 IQVIA: Recent Developments and Future Outlook
Table 6.18 Medpace: Company Snapshot
Table 6.19 Medpace: Recent Developments and Future Outlook
Table 6.20 NorthWest EHealth: Company Snapshot
Table 6.21 NorthWest EHealth: Recent Developments and Future Outlook
Table 6.22 Optum Insight: Company Snapshot
Table 6.23 Optum Insight: Recent Developments and Future Outlook
Table 6.24 Oracle: Company Snapshot
Table 6.25 Oracle: Recent Developments and Future Outlook
Table 6.26 PAREXEL: Company Snapshot
Table 6.27 PAREXEL: Recent Developments and Future Outlook
Table 6.28 Perkin Elmer: Company Snapshot
Table 6.29 Perkin Elmer: Recent Developments and Future Outlook
Table 6.30 SAS: Company Snapshot
Table 6.31 SAS: Recent Developments and Future Outlook
Table 6.32 Syneos Health: Company Snapshot
Table 6.33 Syneos Health: Recent Developments and Future Outlook
Table 6.34 TriNetX: Company Snapshot
Table 6.35 TriNetX: Recent Developments and Future Outlook
Table 7.1 List of Leading Clinical Trials by Enrolled Patient Population
Table 7.2 List of Clinical Trials for COVID-19
Table 10.1 List of Global Events Related to Real World Evidence, 2017-2020
Table 14.1 List of Use Cases Related to Real World Evidence, 2016-2020
Table 15.1 Survey Analysis: Overview of Respondents
Table 15.2 Survey Analysis: Designation and Seniority Level of Respondents
Table 15.3 Survey Analysis: Types of Services Offered
Table 15.4 Survey Analysis: Real World Data Sources
Table 15.5 Survey Analysis: Applications of Real World Evidence
Table 15.6 Survey Analysis: Key Challenges
Table 15.7 Survey Analysis: Extent of Outsourcing
Table 15.8 Survey Analysis: Average Budget Allocated by Big Pharmaceutical Companies
Table 16.1 FDA Issued COVID-19 Projects Related to Real World Evidence
Table 18.1 Data2Life: Company Snapshot
Table 18.2 Adarna Health Data: Company Snapshot
Table 18.3 RTI Health Solutions: Company Snapshot
Table 18.4 Clinerion: Company Snapshot
Table 18.5 uMotif: Company Snapshot
Table 18.6 Savana: Company Snapshot
Table 19.1 Drug Development Costs: Historical Trend (USD Million)
Table 19.2 Real World Evidence Solution Providers: Distribution by Year of Establishment
Table 19.3 Real World Evidence Solution Providers: Distribution by Company Size
Table 19.4 Real World Evidence Solution Providers: Distribution by Location of Headquarters
Table 19.5 Real World Evidence Solution Providers: Distribution by Type of Business Model
Table 19.6 Real World Evidence Solution Providers: Distribution by Type of Services Offered
Table 19.7 Real World Evidence Solution Providers: Distribution by Real World Data Sources
Table 19.8 Real World Evidence Solution Providers: Distribution by Key Applications
Table 19.9 Tree Map Representation: Distribution by Company Size and Applications of Real World Evidence
Table 19.10 Real World Evidence Solution Providers: Distribution by Key Therapeutic Areas
Table 19.11 Clinical Trial Analysis: Distribution by Trial Status
Table 19.12 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year
Table 19.13 Clinical Trial Analysis: Geographical Distribution by Number of Trials
Table 19.14 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Table 19.15 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Table 19.16 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 19.17 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Trial Recruitment Status
Table 19.18 Clinical Trial Analysis: Distribution by Type of Study
Table 19.19 Clinical Trial Analysis: Distribution by Trial Registration Year and Type of Study
Table 19.20 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 19.21 Clinical Trial Analysis: Most Active Industry Players
Table 19.22 Clinical Trial Analysis: Most Active Non-Industry Players
Table 19.23 Clinical Trial Analysis: Distribution by Key Therapeutic Areas
Table 19.24 Clinical Trial Analysis: Distribution by Trial Registration Year and Key Therapeutic Areas
Table 19.25 Clinical Trial Analysis: Leading Indications
Table 19.26 Clinical Trial Analysis: Year Wise Trend of Trials Conducted by Leading Industry Players, 2013-2020
Table 19.27 Clinical Trial Analysis: Benchmarking of Leading Industry Players by Number of Trials Across Key Therapeutic Areas
Table 19.28 Publication Analysis: Distribution by Type of Publication
Table 19.29 Publication Analysis: Cumulative Year-wise Trend, (2016-Q3 2020)
Table 19.30 Publication Analysis: Distribution by Key Focus Areas
Table 19.31 Publication Analysis: Distribution by Real World Data Sources
Table 19.32 Publication Analysis: Key Indications in Terms of Number of Published Studies
Table 19.33 Publication Analysis: Distribution by Type of Sponsors
Table 19.34 Publication Analysis: Most Active Industry Players in Terms of Number of Published Studies
Table 19.35 Publication Analysis: Geographical Distribution of Authors
Table 19.36 Publication Analysis: Key Journals (in Terms of Number of Published Studies)
Table 19.37 Publication Analysis: Key Journals by Impact Factor (In Terms of Impact Factor)
Table 19.38 Publication Analysis: Most Popular Authors
Table 19.39 Trends on Social Media: Cumulative Year-wise Analysis by Volume of Tweets, 2013-H1 2018
Table 19.40 Global Events Analysis: Cumulative Half Year-wise Trend, H1 2017-2021
Table 19.41 Global Events Analysis: Distribution by Event Platform
Table 19.42 Global Events Analysis: Distribution by Event Location
Table 19.43 Global Events Analysis: Distribution by Type of Event
Table 19.44 Global Events Analysis: Most Active Event Organizers
Table 19.45 Global Events Analysis: Most Active Industry Players (in terms of Event Participation
Table 19.46 Global Events Analysis: Most Active Non-Industry Players (in terms of Event Participation
Table 19.47 Global Events Analysis: Distribution by Designations of Event Participants
Table 19.48 Global Events Analysis: Distribution by Affiliated Departments of Event Participants
Table 19.49 Global Real World Evidence Market Opportunity, 2021-2030 (USD Million)
Table 19.50 Real World Evidence Market Opportunity, 2021-2030: Distribution by Different Type of Real World Data Sources
Table 19.51 Real World Evidence Market Opportunity from Medical Claims Data, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.52 Real World Evidence Market Opportunity from Clinical Trials Data, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.53 Real World Evidence Market Opportunity from Clinical Settings Data, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.54 Real World Evidence Market Opportunity from Patient-Powered Data, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.55 Real World Evidence Market Opportunity from Other Types of Data, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.56 Real World Evidence Market Opportunity, 2021-2030: Distribution by Therapeutic Areas
Table 19.57 Real World Evidence Market Opportunity for Autoimmune Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.58 Real World Evidence Market Opportunity for Cardiovascular Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.59 Real World Evidence Market Opportunity for Infectious Diseases, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.60 Real World Evidence Market Opportunity for Metabolic Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.61 Real World Evidence Market Opportunity for Neurological / Psychiatric Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.62 Real World Evidence Market Opportunity for Oncological Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.63 Real World Evidence Market Opportunity for Respiratory Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.64 Real World Evidence Market Opportunity for Other Types of Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.65 Real World Evidence Market Opportunity, 2021-2030: Distribution by Key Applications
Table 19.66 Real World Evidence Market Opportunity in Early Stage Research, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.67 Real World Evidence Market Opportunity in Clinical Development, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.68 Real World Evidence Market Opportunity in Regulatory Approval, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.69 Real World Evidence Market Opportunity in Pricing / Reimbursement, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.70 Real World Evidence Market Opportunity in Post-Approval Studies, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.71 Real World Evidence Market Opportunity, 2021-2030: Distribution by Geography
Table 19.72 Real World Evidence Market Opportunity in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.73 Real World Evidence Market Opportunity in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.74 Real World Evidence Market Opportunity in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.75 Real World Evidence Market Opportunity in Latin America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.76 Real World Evidence Market Opportunity in MENA, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.77 Real World Evidence Market Opportunity in Rest of the World, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.78 Overall Real World Evidence Market Opportunity, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.79 Survey Analysis: Distribution by Type of Organization
Table 19.80 Survey Analysis: Distribution by Location of Organization
Table 19.81 Survey Analysis: Distribution by Seniority Level
Table 19.82 Survey Analysis: Distribution by Types of Services Offered
Table 19.83 Survey Analysis: Distribution by Real World Data Sources
Table 19.84 Survey Analysis: Distribution by Applications of Real World Evidence Generation
Table 19.85 Survey Analysis: Distribution by Key Challenges
Table 19.86 Survey Analysis: Distribution by Extent of Outsourcing
Table 19.87 Survey Analysis: Distribution by Average Budget Allocated by Big Pharmaceutical Companies

Executive Summary

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the real world evidence market in the short-mid term and long term.

Chapter 3 is an introductory chapter that presents a general overview of investment required for developing new medical products, along with information on the limitations associated with randomized clinical trials. Further, it features a detailed discussion on the growing importance of real world evidence and its potential to complement RCTs in healthcare decision-making. It also includes a description of how real world evidence insights is generated from raw, unstructured data, along with details on different sources of data, and the potential applications of this novel approach. Further, the chapter features a discussion on the key growth drivers and roadblocks related to real world evidence, and the novel technologies that are likely to have a notable impact on this industry’s evolution over the coming decade.

Chapter 4 provides a detailed description on the primary elements of data governance and regulatory framework related to real world evidence across various geographies, namely North America (the US and Canada), Europe (the UK, Germany, France, Spain and Italy), and Asia-Pacific and rest of the world (Australia, China and Japan).

Chapter 5 provides a detailed assessment of the industry players that claim to offer real world evidence solutions. The chapter presents analysis of these players on the basis of the year of establishment, company size (in terms of number of employees), location of headquarters, type of services offered (real world data, analytics, consulting and services), real world data sources (medical claims, clinical trials, clinical setting, pharmacy, patient-powered and others), and target application areas (early stage research, clinical development, regulatory submission / reimbursement / market access, and post-approval studies).

Chapter 6 features profiles of prominent real world evidence service providers. Each company profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key members of the executive team), details related to their respective portfolio of technologies / platforms / services, recent developments and an informed future outlook.

Chapter 7 presents a detailed geographical clinical trial analysis of completed, ongoing and planned studies conducted in the real world setting based on the multiple parameters, such as current trial status, trial registration year, regional distribution, enrolled patient population, type of study, leading industry and non-industry players, emerging focus areas and key therapeutic areas. It also highlights the clinical trials conducted for the novel COVID-19 disease. Further, it presents a benchmarking analysis of the leading industry players (in terms of the number of trials conducted). 

Chapter 8 provides information on certain recent publications that we came across during our research on real world evidence. This chapter features a detailed analysis the key prevalent trends associated with these publications, including information on type of publication, year of publication, study objective, popular keywords, types of real world datasets utilized, key disease indications, type of publisher, leading players (in terms of number of publications), region, and key journals (in terms of number of articles published in this domain and impact factor of the journal) to offer better insights on the emerging trends in this area. 

Chapter 9 provides insights on the popularity of real world evidence on the social media platform, Twitter. The chapter highlights the yearly distribution of tweets posted on the platform in the last few years and the most significant events responsible for increase in the volume of tweets each year. Additionally, the chapter showcases the most frequently mentioned keywords, real world data sources, target applications, therapeutic areas and players, on the social media platform. It elucidates the most prolific authors and presents a bubble analysis of the most influential authors related to real world evidence on Twitter.

Chapter 10 presents the insights obtained from a detailed analysis of the events organized for stakeholders in this domain. In addition, the chapter provides details on the different agendas of the summits / forums / conferences / workshops that have been conducted over the last few years or are planned to be held in the coming years.  The analyses presented in the chapter are based on different parameters related to the shortlisted global events, such as the date of event, location, type of event and focus area, organizer, and most active stakeholders, and designations / affiliated departments of the participants. 

Chapter 11 presents information on the needs of different stakeholders (manufacturers, regulators, payers, providers and patients) involved in this domain. The chapter qualitatively assesses the real world evidence related needs of each stakeholder group and the relative importance of their expectations within this domain.

Chapter 12 provides a detailed acquisition target analysis, taking into consideration the historical trend of the activity of the companies that have acquired other firms, and offering a means for other industry stakeholders to identify potential acquisition targets.

Chapter 13 provides details on the key parameters and trends that are likely to influence the future of the real world evidence market, under a comprehensive SWOT framework. The chapter also features a schematic Harvey ball analysis to highlight the relative impact of each SWOT parameter on the overall real world evidence market.

Chapter 14 provides a comprehensive list of notable real world evidence use cases of pharmaceutical / medical device companies in the recent past (since 2016). The chapter highlights how these companies leveraged real world evidence to support their regulatory decisions, advance disease understanding and clinical guidelines, and assist outcome-based reimbursement decisions. In addition, the chapter presents an insightful opportunity analysis, estimating the existing market size and potential growth opportunities of real world evidence across different applications (early stage research, clinical development, regulatory approval, pricing / reimbursement, and post-approval studies). Based on multiple parameters, such as number of pre- or post-approval studies conducted annually, investment associated with these studies, and the likely cost and time saving opportunities, we have provided an informed estimate on the likely evolution of the market over the period 2021-2030. In addition, the report provides detailed market segmentation on the basis of type of real world data sources (medical claims, clinical trials, clinical setting, patient-powered and other data sources), therapeutic area (autoimmune disorders, cardiovascular disorders, infectious diseases, metabolic disorders, neurological / psychiatric disorders, oncological disorders, respiratory disorders and other disorders), and the geographical distribution of the market (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World). 

Chapter 15 presents the insights generated from a detailed survey, wherein we invited multiple stakeholders involved in the real world evidence domain. The participants, who were primarily Directors / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their offerings and the associated commercial potential.

Chapter 16 highlights the impact of COVID-19 outbreak on the real world evidence market. In addition, it features a brief discussion on the key initiatives undertaken by players.

Chapter 17 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario.

Chapter 18 is a collection of transcripts of interviews conducted with various key stakeholders during the course of this study. We have presented the details of our discussions with Limor BH Epstein (Founder, Data2Life), Anonymous (Vice President, Big Pharmaceutical Company), Wirth Peter (Vice President, RTI Health Solutions), Douglas Drake (Senior Director, Clinerion), Fernando Santa (Chief Operating Officer, Adarna Health Data), Jonathan Moshinsky (Chief Strategy Officer, uMotif), and Anonymous (Savana).

Chapter 19 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

• 2 GL Outsourcing
• 23andMe
• 8KMiles
• AbbVie
• Acceliant
• Accenture
• Accsight
• Adarna Health Data
• Adelphi Real World
• Advera Health Analytics
• Aetion
• AG Mednet
• Aixial
• Akeso Medical Holdings
• Allergan
• Allscripts
• Alpha MD
• AMA Innovation Lab
• Amazon Web Services
• American College of Cardiology
• Amgen
• Ana Health
• Anne Arundel Medical Center
• Anthem
• Arcana Institute
• Arena International Events
• Arm
• AstraZeneca
• ASUS Life
• ATAI Life Sciences
• Atrium Health
• Axonal-Biostatem
• Axtria
• Bayer
• BC Platforms
• Beth Israel Deaconess Medical Center
• Bio Valley
• Biocruces Bizkaia Health Reseach Institute
• Bioserv
• Boehringer Ingelheim
• Boston Health Economics 
• Boston Scientific Corporation
• Boston University
• Bridge Medical
• Brigham and Women's Hospital
• Bristol-Myers Squibb
• Cambridge Healthtech Institute
• Cambridgeshire Community Reuse and Recycling Network
• Carevive
• CB Insights
• CBI Events
• Cegedim Strategic Data (CSD)
• Celeri Health
• Centers for Disease Control and Prevention
• Centre Hospitalier Intercommunal Robert Ballanger
• Certara
• CHA Medical Group
• Chinese Biopharmaceutical Association 
• Ciox Health
• Cisiv
• CitiusTech
• CK Aspire
• Clarivate Analytics
• Cleveland Clinic
• Clinakos
• ClinaMetrics
• Clinerion
• Clinical Practice Research Datalink
• Clinical Trial EndPoint
• Clinigen Group
• Cloudera
• CloudMoyo
• Cluell
• Cogentia Healthcare Consulting
• Cognizant 
• conferenceseries.com
• ConvergeHEALTH by Deloitte
• Corrona
• Cota Healthcare
• Covance
• Crossix Solutions
• CSS
• CTI Clinical Trial and Consulting Services
• Custodix
• Cytel
• D Cube Analytics
• Daiichi Sankyo
• Dartmouth-Hitchcock Medical Center
• Data2Life
• Databricks
• Datavant
• DCC 
• Decision Driver Analytics
• Decision Resources Group
• Dendrite Clinical Systems
• DHIS2
• DIGIPHARM
• Digital Health Labs
• Diplomat
• docdok.health
• Dresden International University
• Drug Information Association
• Drug Intelligence
• Duke Company
• Duke University
• Duke-Margolis Center for Health Policy
• Duke-NUS Medical School
• DuPage Medical Group
• eClinical Forum
• Econcare
• Eli Lilly
• Elligo Health Research
• Ephicacy
• EPID Research
• EPM Group
• ERN GUARD-Heart
• Ernst & Young Global
• ESiOR
• EUCROF
• European Medicines Agency
• European Society of Cardiology
• EVERSANA
• Evex Medical
• Evidence Based Solutions
• Evidera
• Evidilya
• Excelra
• ExL Events 
• eyeforpharma
• Financial Times
• Flatiron Health
• Flex
• Food and Drug Law Institute 
• Friends of Cancer Research
• Fuzzy Logix
• Gate2Biotech
• Genentech
• Genospace
• GlaxoSmithKline
• GNS Healthcare
• Graticule
• GSK
• Hanson Wade
• Happy Life Technology
• Harvard Medical School
• Harvard Pilgrim Health Care Institute 
• Healiant
• Healint
• Health Canada
• Health IQ
• Health Solutions
• Health Technology Assessment international
• Healthagen
• Healthcare Information and Management Systems Society
• HealthCore
• Healthing Research
• HealThink
• HealthVerity
• Hospital Clinic of Barcelona
• Hospital Costa del Sol
• Hospital de Basurto
• Hospital del Mar
• Hospital Galdakao-Usansolo
• Hospital São Domingos
• Hospital Universitario Araba
• Hospital Universitario Donostia
• Houston Methodist Hospital 
• Huron
• IBC Asia
• IBM Watson Health (IBM)
• iClusion
• ICON
• Idorsia
• IEEE
• Ignite Data
• IMI GetReal
• Imperial College Health Partners
• Indegene
• Infosys
• Ingress Health
• Innovation Enterprise
• Inovalon
• Insight Pharma Services
• Institute of Statistical, Social and Economic Research
• Instituto de Salud Carlos III
• Intel
• Inteliquet
• International Business Machines
• International Center for Entrepreneurial Development
• International Coalition of Medicines Regulatory Authorities
• International Society for Pharmacoeconomics and Outcomes Research
• International Society for Pharmacoeconomics and Outcomes Research
• IntrinsiQ Specialty Solutions
• IQVIA
• Istituto Auxologico Italiano
• iTakeControl
• iwantGreatCare
• Janssen
• JDRF
• Johaus Global
• Johns Hopkins University
• Kaiku Health
• Kaiser Permanente
• Kantar Health
• Keyrus Biopharma
• KNect365
• Koneksa Health
• Kx Systems
• LINK Medical Research
• LMC Manna Research
• London School of Economics and Political Science
• LynxCare
• M2Gen
• M2S
• MA Provider
• MakroCare
• MAP BioPharma
• MAP Group (Acquired by ICON)
• marcus evans
• MarketsandMarkets
• MarkLogic
• MarksMan Healthcare Communications
• Massachusetts General Hospital
• Massachusetts Institute of Technology  
• MaxisIT
• Mayo Clinic
• McDougall Scientific
• McKesson
• MDC Partners
• MeaningCloud
• Medaffcon
• Med-e Share
• MedEngine
• Medialis
• Medical College of Wisconsin
• Medical Wisdom Consulting Group
• Medidata
• Medimix International (Acquired by Evidera)
• MeDiNova Research
• Medlior Health Outcomes Research 
• Medpace
• MedPass International 
• MedSoft
• Medstreaming
• Medtronic
• Medway NHS Foundation Trust
• Meiji Pharmaceutical University 
• Merck
• Mercy Technology Services
• Metaforms
• Methodist Health System
• Model Answers 
• MolecularMD (Acquired by ICON)
• MyOwnMed
• National Association of Managed Care Physicians 
• National Cancer Institute
• National Health Service Trust
• National Institute for Health and Care Excellence
• National Institutes of Health
• National Research Center for Preventive Medicine
• Neox
• Noona
• Nordic HTA
• Northern Alberta Clinical Trials and Research Centre
• NorthWest EHealth
• Novartis
• Novo Nordisk
• Numerus
• NYU Langone Health
• O4 Research
• Observational & Pragmatic Research Institute
• Odysseus Data Services
• OKRA Technologies
• OM1
• Omega CRO
• Oncocare Health Incorporated
• OncoStats
• OPEN Health
• Optra Systems
• OptumInsight
• Opyl
• Oracle
• OrbitalRX
• Oriola
• ORPHA Strategy Consulting
• Orphazyme
• OXON Epidemiology
• Palantir
• PAREXEL
• Patient iP
• PatientsLikeMe
• PatientSource
• PCORnet
• Pentavere
• Peripharm
• PerkinElmer
• Pfizer
• pH Associates
• Pharma Industry Finland
• Pharma Intelligence
• Pharmaceuticals and Medical Devices Agency (PMDA)
• PharmaLand Consulting Group
• Pharmerit International
• PHARMO Institute for Drug Outcomes Research
• phUSE
• Pitié-Salpêtrière University Hospital
• Point-of-Care Partners
• PotentiaMED
• PRA Health Sciences
• Precision Digital Health
• Premier
• Provisio
• Public Health England
• Qlik
• Quantify Research
• Quantzig
• Raven Biosciences
• Real Consulting Data
• REAL Europe
• Real Life Sciences
• RealHealthData
• Reuters Events
• Roam
• Roche
• RTI Health Solutions
• RWE Genesys
• RxAnte
• S3 Connected Health
• S4 Research
• Saama Technologies
• Sanofi
• Sino-American Pharmaceutical Professionals Association -Greater Philadelphia 
• Sapungo
• SAS
• Savana
• Sciformix
• Self Care Catalysts
• Semicrol
• Sentry Data Systems
• SerenaGroup
• SHYFT Analytics
• SmartAnalyst
• SMi Group
• Society for Clinical Research Sites
• Southwood Research
• Spanish Data Protection Agency
• SPRIM Advanced Life Sciences
• SQN Clinical 
• St George's University Hospitals NHS Foundation Trust
• Stanford University
• StatFinn
• Strategy Institute
• SVMPharma
• Syapse
• Symphony Health Solutions
• Syneos Health
• Synergus
• Syntel
• Takeda Pharmaceuticals
• Talking Medicines
• Talosix
• Target RWE
• TCD Outcomes Research
• TCD Research
• TCR Solutions
• Techtrials International
• Tempus
• Terrapinn Holdings
• TFS
• Accelerated Cure Project
• The Association of the Pharmaceutical Industry in Norway
• European Epidemiological Forum
• The Evidence Base
• The Health and Medicine Division
• The National Patient-Centered Clinical Research Network 
• The Wound Treatment Center
• Thomas Jefferson University
• TriNetX
• Trinity Industries
• T-Systems
• TTi Healthcare and Economics
• Tufts Center for the Study of Drug Development
• Turacoz Healthcare Solutions
• U.S. Department of Veterans Affairs
• UCSF-Stanford Center of Excellence in Regulatory Science and Innovation
• uMotif
• United BioSource (UBC)
• United States Food and Drug Administration
• University College London
• University Hospitals
• University Hospital of the Nuestra Senora de Candelaria
• University of Amsterdam
• University of California
• University of Cambridge
• University of Colorado
• University of Ghana
• University of Michigan
• University of Minnesota
• University of North Carolina
• University of Pennsylvania
• University of Pittsburgh
• University of Southern California
• University of Wisconsin
• VA Office of Research and Development
• Validic
• Vecna
• Verana Health
• Verantos
• Verily Life Sciences
• Vestrum Health
• Vitaccess
• Vital Statistics Consulting
• Vonlanthen Group
• Wake Forest University Health Sciences
• Wellframe
• West Monroe Partners
• William Beaumont Hospital
• Wipro
• World Congress
• Worldwide Clinical Trials
• Xcenda
• xCures
• Yale University
• Zeblok
• ZEINCRO
• Zem Solutions
• Zephyr Health
• ZM Company
• ZS Company

Methodology